Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Sorrell

Surgery Sioux Falls, SD Medical Doctor

NPI 1972577757 CMS profile 135138

1508 W 22Nd St, Suite 101, Sioux Falls, SD 57105

Open in the dashboard

General payments

$8,997

74 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Sorrell of Sioux Falls, SD is reported in the CMS Open Payments database as having received $8,997 across 74 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,456 18
2024 General $309 6
2023 General $6,584 31
2022 General $151 5
2020 General $27 1
2019 General $471 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Sorrell
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Matthew Sorrell were reported at $1,456. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Matthew Sorrell Surgery median Middle half National median
2019 $471 $253 $82–$1,521 $163
2020 $27 $131 $40–$706 $114
2021 $0 $168 $50–$904 $132
2022 $151 $224 $76–$1,218 $149
2023 $6,584 $253 $82–$1,255 $160
2024 $309 $279 $90–$1,381 $164
2025 $1,456 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $5,195 18 payments
  2. Davol Inc. $2,788 25 payments
  3. Z-Medica, LLC $229 4 payments
  4. CONMED Corporation $145 2 payments
  5. Boston Scientific Corporation $90 1 payment
  6. Covidien LP $75 3 payments
  7. Integra LifeSciences Corporation $74 3 payments
  8. Hologic, LLC $68 2 payments
  9. Endogastric Solutions, Inc $57 1 payment
  10. Vertex Pharmaceuticals Incorporated $55 3 payments
  11. Other $221 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,313 13 payments
  2. Education $3,000 1 payment
  3. Food and Beverage $2,466 56 payments
  4. Consulting Fee $202 3 payments
  5. Gift $16 1 payment
Products named General payments · program years 2019–2025
  1. DAVINCI XI $3,000 1 payment
  2. Phasix Mesh $2,718 22 payments
  3. Da Vinci Surgical System $2,195 17 payments
  4. QuikClot $202 3 payments
  5. Control+ $202 3 payments
  6. AIRSEAL $145 2 payments
  7. VISICLEAR $117 1 payment
  8. General Therapies $90 1 payment
  9. Integra Recon-Skin And Wound $74 3 payments
  10. Integra Recon-Skin And Wound $74 3 payments
  11. Other $916 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

221

Median for General Surgery: 59

Drug cost

$3,318

Median for General Surgery: $393

Branded share of claims

43.4%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 59 $1,617
Cholestyramine Light Cholestyramine Brand 20 $1,202
Omeprazole Generic 14 $141
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 17 $82
Neomycin Sulfate Generic 14 $79
Gabapentin Generic 19 $72
Amitriptyline Hcl Generic 13 $36
Metronidazole Generic 15 $33
Lansoprazole Generic 11 $23
Ondansetron Hcl Generic 23 $20

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 130 billing codes

Paid by Medicare

$119,406

Medicare's payments for the services billed

Medicare patients

304

Average age 72

Services billed

743

151 women, 153 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 50%
Ischemic heart disease 37%
Chronic kidney disease 29%
Diabetes 28%
Atrial fibrillation 27%
Cancer 26%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

74 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record